For new and old investors, taking full advantage of the stock market and investing with confidence are common goals.
While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics.
Finding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to highlight the most attractive and discounted stocks.
San Diego, CA.-based Illumina Inc. provides sequencing and array-based solutions for genetic and genomic analysis across a wide range of markets, driving their adoption in research and clinical settings.Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals as well as pharmaceutical, biotechnology, commercial molecular diagnostic and consumer genomics companies.
ILMN boasts a Value Style Score of B and VGM Score of A, and holds a Zacks Rank #3 (Hold) rating. Shares of Illumina are trading at a forward earnings multiple of 19.1X, as well as a PEG Ratio of 1.4, a Price/Cash Flow ratio of 18.3X, and a Price/Sales ratio of 3.1X.
Many value investors pay close attention to a company's earnings as well. For ILMN, seven analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.09 to $4.49 per share for 2025. Per share ILMN boasts an average earnings surprise of 106.1%.
Investors should take the time to consider ILMN for their portfolios due to its solid Zacks Ranks, notable earnings and valuation metrics, and impressive Value and VGM Style Scores.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Illumina, Inc. (ILMN) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。